REGADENOSON

Search structure
Trade Names:
Synonyms:
Status: Approved (2008)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: C01EB21
UNII: 2XLN4Y044H

Structure
InChI Key LZPZPHGJDAGEJZ-AKAIJSEGSA-N
Smile CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1
InChI
InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C15H20N8O6
Molecular Weight 408.38
AlogP -2.43
Hydrogen Bond Acceptor 12.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 4.0
Polar Surface Area 186.46
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 28.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Adenosine A2a receptor agonist
Primary Target
A2A receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference

Related Entries

MCS

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Cardiac disorders Dyspnoea 29.0
Cardiac disorders Dyspnoea 28.0
Nervous system disorders Headache 27.0
Cardiac disorders Dyspnoea 26.0
Nervous system disorders Headache 26.0
General disorders and administration site conditions Flushing 25.0
General disorders and administration site conditions Flushing 23.0
Cardiac disorders Chest pain 19.0
Cardiac disorders Angina pectoris 18.0
Cardiac disorders Chest discomfort 18.0
Cardiac disorders Chest pain 18.0
Cardiac disorders Dyspnoea 18.0
Investigations Electrocardiogram ST segment depression 18.0
Nervous system disorders Headache 17.0
General disorders and administration site conditions Flushing 16.0
Gastrointestinal disorders Abdominal discomfort 15.0
Cardiac disorders Chest discomfort 13.0
Cardiac disorders Chest pain 13.0
Cardiac disorders Angina pectoris 12.0
Investigations Electrocardiogram ST segment depression 12.0
Cardiac disorders Dizziness 11.0
Cardiac disorders Dyspnoea 10.7
Cardiac disorders Chest pain 10.0
Cardiac disorders Dizziness 8.0
General disorders and administration site conditions Feeling hot 8.0
Cardiac disorders Chest pain 7.0
Cardiac disorders Dizziness 7.0
Gastrointestinal disorders Dysgeusia 7.0
Gastrointestinal disorders Nausea 6.0
Gastrointestinal disorders Abdominal discomfort 5.0
Gastrointestinal disorders Dysgeusia 5.0
General disorders and administration site conditions Feeling hot 5.0
Respiratory, thoracic and mediastinal disorders Wheezing 3.1
Cardiac disorders Dyspnoea
Gastrointestinal disorders Abdominal discomfort 2.0
Cardiac disorders Dyspnoea
Respiratory, thoracic and mediastinal disorders Wheezing
Respiratory, thoracic and mediastinal disorders Wheezing 0.9
Respiratory, thoracic and mediastinal disorders Wheezing

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Cardiac disorders
16.87
Nervous system disorders
15.44
General disorders and administration site conditions
14.18
Gastrointestinal disorders
9.8
Vascular disorders
8.48
Injury, poisoning and procedural complications
8.12
Respiratory, thoracic and mediastinal disorders
6.96
Investigations
5.8
Musculoskeletal and connective tissue disorders
4.13
Skin and subcutaneous tissue disorders
3.32
Psychiatric disorders
2.58

Cross References

Resources Reference
CAS NUMBER 313348-27-5
ChEMBL CHEMBL3989695
DrugBank DB06213
EPA CompTox DTXSID70236374
FDA SRS 2XLN4Y044H
Guide to Pharmacology 5596
KEGG D05711
PubChem 219024
SureChEMBL SCHEMBL678893
ZINC ZINC13818943
CAS NUMBER 313348-27-5
ChEBI 135613
ChEMBL CHEMBL317052
DrugBank DB06213
DrugCentral 2362
EPA CompTox DTXSID4057712
FDA SRS 2XLN4Y044H
Guide to Pharmacology 5596
KEGG D05711
PharmGKB PA166129536
PubChem 219024
SureChEMBL SCHEMBL678893
ZINC ZINC000013818943
CONTENTS